通化东宝药业股份有限公司 2025 年员工持股计划管理办法 第一章 总则 第一条 为规范通化东宝药业股份有限公司（以下简称"通化东宝"或"公 司"）2025 年员工持股计划（以下简称"本员工持股计划"）的实施，根据《中 华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以 下简称"《证券法》"）、《关于上市公司实施员工持股计划试点的指导意见》（以 下简称"《指导意见》"）及《上海证券交易所上市公司自律监管指引第 1 号—— 规范运作》（以下简称"《自律监管指引 1 号》"）等相关法律、行政法规、规章、 规范性文件和《公司章程》之规定，特制定本管理办法。 第二章 员工持股计划的制定 第二条 员工持股计划所遵循的基本原则 （一）依法合规原则 公司实施员工持股计划，严格按照法律、行政法规的规定履行程序，真实、 准确、完整、及时地实施信息披露。任何人不得利用员工持股计划进行内幕交 易、操纵证券市场等证券欺诈行为。 （二）自愿参与原则 公司实施员工持股计划遵循公司自主决定，员工自愿参与，公司不以摊派、 强行分配等方式强制员工参与员工持股计划。 （三）风险自担原则 员工持股计划参与人盈亏自负，风险 ...

通化东宝药业股份有限公司 2025 年员工持股计划摘要 证券代码：600867 证券简称：通化东宝 通化东宝药业股份有限公司 2025 年员工持股计划 摘要 二〇二五年九月 0 通化东宝药业股份有限公司 2025 年员工持股计划摘要 声 明 本公司及董事会全体成员保证本员工持股计划及其摘要不存在虚假记载、误导性 陈述或重大遗漏，并对其内容的真实性、准确性、完整性承担法律责任。 1 通化东宝药业股份有限公司 2025 年员工持股计划摘要 风险提示 一、通化东宝药业股份有限公司（以下简称"通化东宝"、"公司"）2025 年员 工持股计划（草案）（以下简称"本员工持股计划草案"）需经公司股东会审议通过 后方可实施，本员工持股计划草案能否获得公司股东会批准，存在不确定性。 二、有关公司 2025 年员工持股计划（以下简称"本员工持股计划"）的参与对象、 资金来源、出资金额和具体实施方案等属初步结果，能否完成实施，存在不确定性。 三、员工遵循依法合规、自愿参与、风险自担原则，若员工认购资金较低，本员 工持股计划存在无法成立的风险；若员工认购份额不足，本员工持股计划存在低于预 计规模的风险。 四、股票价格受公司经营业绩、 ...

通化东宝药业股份有限公司 2025 年员工持股计划（草案） 证券代码：600867 证券简称：通化东宝 通化东宝药业股份有限公司 2025 年员工持股计划 （草案） 二〇二五年九月 0 通化东宝药业股份有限公司 2025 年员工持股计划（草案） 声 明 本公司及董事会全体成员保证本员工持股计划及其摘要不存在虚假记载、误导性 陈述或重大遗漏，并对其内容的真实性、准确性、完整性承担法律责任。 1 通化东宝药业股份有限公司 2025 年员工持股计划（草案） 风险提示 一、通化东宝药业股份有限公司（以下简称"通化东宝"、"公司"）2025 年员 工持股计划（草案）（以下简称"本员工持股计划草案"）需经公司股东会审议通过 后方可实施，本员工持股计划草案能否获得公司股东会批准，存在不确定性。 二、有关公司 2025 年员工持股计划（以下简称"本员工持股计划"）的参与对象、 资金来源、出资金额和具体实施方案等属初步结果，能否完成实施，存在不确定性。 三、员工遵循依法合规、自愿参与、风险自担原则，若员工认购资金较低，本员 工持股计划存在无法成立的风险；若员工认购份额不足，本员工持股计划存在低于预 计规模的风险。 四、股票价格 ...

Core Insights - The article highlights the innovative financial services and products being developed in Tonghua City to address the challenges of the aging population and insufficient pension supply [1][2][3][4] Group 1: Financial Innovations - The People's Bank of China in Tonghua has supported the elderly care industry by innovating credit products and optimizing financial services, resulting in a loan balance of 183 million yuan for the elderly care industry, with a year-on-year growth of 73.97% as of June 2025 [1] - The establishment of specialized credit mechanisms such as "Elderly Care Loan" and "Health Care Pass" has been initiated to support the integration of medicine and elderly care, focusing on new business models like traditional Chinese medicine health care and smart elderly care [2] - The "Elderly Care Institution Construction Loan" allows for a loan amount up to 80% of the annual fee income from existing beds, with a maximum loan term of 10 years, addressing the long-term funding needs of elderly care facilities [3] Group 2: Community Engagement and Support - Financial institutions in Tonghua have implemented 37 types of facilities to assist the elderly, including large-print materials and anti-fraud education, enhancing the accessibility of financial services for seniors [4] - The local banks have actively engaged with the community, conducting over 130 outreach events and distributing more than 23,000 informational brochures to educate seniors on financial matters [4] - The People's Bank of China in Tonghua plans to promote more pension financial products and inclusive elderly care financial management to benefit a larger segment of the elderly population [4]

Investment Rating - The investment rating for Tonghua Dongbao is maintained at "Accumulate" [2] Core Views - The company is accelerating the overseas commercialization of multiple products, leveraging stable product quality and a diverse product portfolio to expand into international markets. Strategic partnerships have been established, including a collaboration with Jianyou Co. to enter the U.S. insulin market. The company has also received approvals for its insulin products in various countries [7] - The company is actively innovating and transforming its product offerings. The GLP-1 product, Liraglutide, has been launched domestically, and the company is working with Sinovac to expedite its registration in 17 emerging markets. Additionally, two innovative GLP-1 drugs are in clinical trials, showing promising results [7] - Financial projections indicate that the company is expected to achieve revenues of 2.5 billion, 3.08 billion, and 3.31 billion yuan for the years 2025, 2026, and 2027 respectively, with corresponding net profits of 446 million, 721 million, and 874 million yuan. The projected PE ratios are 36.9, 22.8, and 18.8 for the same years [6][7] Financial Summary - The company's revenue for 2023 is projected at 3,075 million yuan, with a significant decline expected in 2024 to 2,010 million yuan, followed by a recovery to 2,500 million yuan in 2025. The revenue growth rates are forecasted at 10.7% for 2023, -34.7% for 2024, and 24.4% for 2025 [6][8] - The net profit for 2023 is estimated at 1,168 million yuan, with a loss of 43 million yuan anticipated in 2024, and a return to profitability with 446 million yuan in 2025. The net profit growth rates are -26.2% for 2023 and -103.7% for 2024, with a projected recovery of 61.7% in 2025 [6][8] - The company's EPS is expected to be 0.59 yuan in 2023, dropping to -0.02 yuan in 2024, and recovering to 0.23 yuan in 2025 [6][8]

Group 1 - The article highlights the increasing presence of global sovereign wealth funds in the A-share market, with notable funds such as Abu Dhabi Investment Authority, Kuwait Investment Authority, and Singapore Government Investment Corporation appearing among the top ten shareholders of several A-shares [1][2] - As of the end of Q2 this year, Abu Dhabi Investment Authority held 19 A-shares with a total of 376 million shares valued at 8 billion yuan, showing significant increases compared to the end of Q1 [1][2] - Kuwait Investment Authority holds 8 A-shares with a total of 100 million shares valued at 1.98 billion yuan, having recently entered the top ten shareholders of companies like Giant Star Technology and Kunming Pharmaceutical Group [2] Group 2 - Recent data indicates a notable increase in international capital interest in the A-share market, with nearly 60% of sovereign wealth funds planning to increase their allocation to Chinese assets over the next five years, driven by attractive investment returns and market diversification [2] - The Chief Investment Officer of Allianz Fund, Zheng Yuchen, stated that China is demonstrating leading advantages in areas such as artificial intelligence, which is gaining global recognition, thereby enhancing domestic and international investor confidence [3]

Core Viewpoint - Tonghua Dongbao (600867) reported significant growth in both revenue and net profit for the first half of 2025, with total revenue reaching 1.373 billion yuan, up 85.6% year-on-year, and net profit attributable to shareholders at 218 million yuan, up 194.48% year-on-year [1] Financial Performance - Total revenue for Q2 2025 was 722 million yuan, reflecting a substantial increase of 385.77% year-on-year, while net profit for the same period was 109 million yuan, up 124.39% year-on-year [1] - Gross margin stood at 71.45%, a decrease of 2.05% year-on-year, while net profit margin increased to 15.16%, up 148.67% year-on-year [1] - Total operating expenses (sales, management, and financial expenses) amounted to 678 million yuan, accounting for 49.36% of revenue, a decrease of 31.42% year-on-year [1] Cash Flow and Financial Position - Cash and cash equivalents increased by 89.02% due to the receipt of advance payments for the transfer of shares and increased operating revenue [3] - The net cash flow from financing activities rose by 25.51%, attributed to increased bank borrowings [4] - The company’s cash flow situation is under observation, with cash and cash equivalents to current liabilities ratio at 88.47% [4] Inventory and Sales Dynamics - The significant increase in revenue (85.6%) was driven by a notable rise in sales of insulin analog products, alongside adjustments in inventory management from the previous year [2] - Operating costs surged by 95.88%, correlating with the substantial increase in sales volume of insulin products [2] Investment and Market Position - The company has seen a 71.08% increase in R&D expenses, indicating a focus on innovation and product development [6] - The company’s historical financial performance shows a median ROIC of 17.23% over the past decade, although the lowest recorded ROIC was -0.53% in 2024, suggesting variability in investment returns [6] Fund Holdings - The largest fund holding Tonghua Dongbao is the Galaxy Medical Mixed A Fund, which has recently entered the top ten holdings with 3.0773 million shares [5]

Core Viewpoint - Tonghua Dongbao (600867) reported significant growth in both revenue and net profit for the first half of 2025, indicating a strong recovery and operational improvement compared to the previous year [1]. Financial Performance - Total revenue reached 1.373 billion yuan, an increase of 85.6% year-on-year [1]. - Net profit attributable to shareholders was 218 million yuan, up 194.48% year-on-year [1]. - In Q2 2025, total revenue was 722 million yuan, reflecting a substantial increase of 385.77% year-on-year [1]. - Q2 net profit attributable to shareholders was 109 million yuan, a rise of 124.39% year-on-year [1]. Profitability Metrics - Gross margin stood at 71.45%, a decrease of 2.05% compared to the previous year [1]. - Net margin improved to 15.16%, a significant increase of 148.67% year-on-year [1]. - Total selling, administrative, and financial expenses amounted to 678 million yuan, accounting for 49.36% of revenue, down 31.42% year-on-year [1]. Cash Flow and Assets - Cash flow from operating activities increased by 147.5%, driven by higher cash receipts from sales [3]. - Cash and cash equivalents rose by 132.26% to 1.109 billion yuan, attributed to the receipt of advance payments for share transfers and increased operating revenue [1][2]. - The company's net asset value per share decreased by 4.58% to 3.13 yuan [1]. Debt and Financing - Interest-bearing debt increased by 137.3% to 852 million yuan, reflecting higher short-term bank borrowings [1][2]. - The company reported a significant increase in other payables, up 814.4%, due to the receipt of advance payments for share transfers [2]. Investment and Market Position - The company has shown a strong recovery in sales, particularly in insulin-like products, which significantly boosted domestic sales revenue [3]. - The business model relies heavily on marketing-driven strategies, necessitating further analysis of the underlying factors [6]. Fund Holdings - The largest fund holding Tonghua Dongbao is the Galaxy Medical Mixed A Fund, which has recently increased its position [8].

格隆汇8月25日丨通化东宝(600867.SH)公布半年度报告，2025年上半年，归属于上市公司股东的净利润 与上年同期相比实现了扭亏为盈。实现营业收入137,349.06万元；实现利润总额25,493.19万元；实现归 属于上市公司股东的净利润21,775.81万元，同比扭亏；实现归属于上市公司股东的扣除非经常性损益的 净利润22,081.94万元。 ...

Core Viewpoint - Tonghua Dongbao Pharmaceutical Co., Ltd. reported significant growth in revenue and profit for the first half of 2025, driven by increased sales of insulin products and successful participation in national drug procurement programs [2][3]. Company Overview and Financial Indicators - The company achieved operating revenue of approximately 1.37 billion yuan, an increase of 85.60% compared to the same period last year [2]. - Total profit reached approximately 254.93 million yuan, a significant recovery from a loss in the previous year [2]. - Net profit attributable to shareholders was approximately 217.76 million yuan, marking a turnaround from a loss in the previous year [2]. - The company’s net assets decreased by 4.11% to approximately 6.12 billion yuan, while total assets increased by 6.35% to approximately 7.85 billion yuan [2]. Industry and Main Business Situation - The company operates in the pharmaceutical manufacturing industry, focusing on drug research, production, and sales, particularly in diabetes and endocrine treatment [3][4]. - The company has a comprehensive product line for diabetes treatment, including human insulin and insulin analogs, and aims to provide integrated solutions for diabetes patients [3][4]. - The company has established a strong market presence in the diabetes treatment sector, with over 40% market share in human insulin, maintaining its position as the industry leader [9][10]. Sales and Marketing Strategy - The company has implemented a specialized sales team and marketing strategies to enhance product coverage and market penetration, particularly in hospitals [12][13]. - The company successfully secured A/A1 class procurement results for its entire insulin product line, significantly increasing its hospital access and market share [14][15]. - The company is actively expanding its international market presence, with several products already approved for sale in various countries [9][10]. Research and Development - The company is committed to innovation, focusing on the development of GLP-1 receptor agonists and other novel drugs to address unmet clinical needs in diabetes and related conditions [10][11]. - The company has multiple innovative drug candidates in various stages of clinical trials, including those targeting diabetes and gout [11][18]. - The company aims to enhance its R&D capabilities and maintain a competitive edge in the pharmaceutical market through continuous innovation [10][11].